相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Nek7 Protects Telomeres from Oxidative DNA Damage by Phosphorylation and Stabilization of TRF1
Rong Tan et al.
MOLECULAR CELL (2017)
Molecular Architecture of Full-length TRF1 Favors Its Interaction with DNA
Jasminka Boskovic et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2016)
Phosphoinositide 3-kinase inhibitors induce DNA damage through nucleoside depletion
Ashish Juvekar et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
PI3K inhibitors as new cancer therapeutics: implications for clinical trial design
Cristian Massacesi et al.
ONCOTARGETS AND THERAPY (2016)
Roles of telomeres and telomerase in cancer, and advances in telomerase-targeted therapies
Mohammad A. Jafri et al.
GENOME MEDICINE (2016)
PI3K/AKT Signaling Pathway Is Essential for Survival of Induced Pluripotent Stem Cells
Amir M. Hossini et al.
PLOS ONE (2016)
Therapeutic inhibition of TRF1 impairs the growth of p53-deficient K-RasG12V-induced lung cancer by induction of telomeric DNA damage
Maria Garcia-Beccaria et al.
EMBO MOLECULAR MEDICINE (2015)
A Pilot Study of the Telomerase Inhibitor Imetelstat for Myelofibrosis
Ayalew Tefferi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Telomerase Inhibitor Imetelstat in Patients with Essential Thrombocythemia
Gabriela M. Baerlocher et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Glycogen synthase kinase-3 (GSK3): Regulation, actions, and diseases
Eleonore Beurel et al.
PHARMACOLOGY & THERAPEUTICS (2015)
A mutation in the POT1 gene is responsible for cardiac angiosarcoma in TP53-negative Li-Fraumeni-like families
Oriol Calvete et al.
NATURE COMMUNICATIONS (2015)
Mice with Pulmonary Fibrosis Driven by Telomere Dysfunction
Juan M. Povedano et al.
CELL REPORTS (2015)
The genomic landscape of mantle cell lymphoma is related to the epigenetically determined chromatin state of normal B cells
Jenny Zhang et al.
BLOOD (2014)
Characterization of the Novel and Specific PI3Kα Inhibitor NVP-BYL719 and Development of the Patient Stratification Strategy for Clinical Trials
Christine Fritsch et al.
MOLECULAR CANCER THERAPEUTICS (2014)
POT1 loss-of-function variants predispose to familial melanoma
Carla Daniela Robles-Espinoza et al.
NATURE GENETICS (2014)
Rare missense variants in POT1 predispose to familial cutaneous malignant melanoma
Jianxin Shi et al.
NATURE GENETICS (2014)
Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation
Pascal Furet et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2013)
POT1 mutations cause telomere dysfunction in chronic lymphocytic leukemia
Andrew J. Ramsay et al.
NATURE GENETICS (2013)
Rapid identification of ETP-46992, orally bioavailable PI3K inhibitor, selective versus mTOR
Sonia Martinez Gonzalez et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2012)
Conditional TRF1 knockout in the hematopoietic compartment leads to bone marrow failure and recapitulates clinical features of dyskeratosis congenita
Fabian Beier et al.
BLOOD (2012)
Whole-Exome Sequencing Studies of Nonhereditary (Sporadic) Parathyroid Adenomas
Paul J. Newey et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor
Sauveur-Michel Maira et al.
MOLECULAR CANCER THERAPEUTICS (2012)
PI3K signalling: the path to discovery and understanding
Bart Vanhaesebroeck et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2012)
Combining a PI3K Inhibitor with a PARP Inhibitor Provides an Effective Therapy for BRCA1-Related Breast Cancer
Ashish Juvekar et al.
CANCER DISCOVERY (2012)
Genomic determinants of P13K pathway inhibitor response in cancer
Britta Weigelt et al.
FRONTIERS IN ONCOLOGY (2012)
Some highlights of research on aging with invertebrates, 2010
Linda Partridge
AGING CELL (2011)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer
V. Serra et al.
ONCOGENE (2011)
Cyclin B-dependent kinase 1 regulates human TRF1 to modulate the resolution of sister telomeres
Megan McKerlie et al.
NATURE COMMUNICATIONS (2011)
Mechanisms of Life Span Extension by Rapamycin in the Fruit Fly Drosophila melanogaster
Ivana Bjedov et al.
CELL METABOLISM (2010)
Discovery of GSK2126458, a Highly Potent Inhibitor of PI3K and the Mammalian Target of Rapamycin
Steven D. Knight et al.
ACS MEDICINAL CHEMISTRY LETTERS (2010)
Phosphorylation of Telomeric Repeat Binding Factor 1 (TRF1) by Akt Causes Telomere Shortening
Yen-Chung Chen et al.
CANCER INVESTIGATION (2009)
Mammalian Telomeres Resemble Fragile Sites and Require TRF1 for Efficient Replication
Agnel Sfeir et al.
CELL (2009)
Increased telomere fragility and fusions resulting from TRF1 deficiency lead to degenerative pathologies and increased cancer in mice
Paula Martinez et al.
GENES & DEVELOPMENT (2009)
TRF1 Controls Telomere Length and Mitotic Fidelity in Epithelial Homeostasis
Purificacion Munoz et al.
MOLECULAR AND CELLULAR BIOLOGY (2009)
Ribosomal Protein S6 Kinase 1 Signaling Regulates Mammalian Life Span
Colin Selman et al.
SCIENCE (2009)
Plk1 phosphorylation of TRF1 is essential for its binding to telomeres
Zhao-Qiu Wu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Regulation of telomeric repeat binding factor 1 binding to telomeres by casein kinase 2-mediated phosphorylation
Mi Kyung Kim et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Separating cause from effect: how does insulin/IGF signalling control lifespan in worms, flies and mice?
M. D. W. Piper et al.
JOURNAL OF INTERNAL MEDICINE (2008)
The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer
Adrian J. Folkes et al.
JOURNAL OF MEDICINAL CHEMISTRY (2008)
Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity
Sauveur-Michel Maira et al.
MOLECULAR CANCER THERAPEUTICS (2008)
PI3K pathway alterations in cancer: variations on a theme
T. L. Yuan et al.
ONCOGENE (2008)
Promotion of Reprogramming to Ground State Pluripotency by Signal Inhibition
Jose Silva et al.
PLOS BIOLOGY (2008)
Telomere length, stem cells and aging
Maria A. Blasco
NATURE CHEMICAL BIOLOGY (2007)
The role of the poly(ADP-ribose) polymerase tankyrase1 in telomere length control by the TRF1 component of the shelterin complex
Jill R. Donigian et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
The p110α isoform of PI3K is essential for proper growth factor signaling and oncogenic transformation
Jean J. Zhao et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism
Jeffrey A. Engelman et al.
NATURE REVIEWS GENETICS (2006)
The F-box protein FBX4 targets PIN2/TRF1 for ubiquitin-mediated degradation and regulates telomere maintenance
TH Lee et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Role of the phosphoinositide 3-kinase pathway in mouse embryonic stem (ES) cells
K Takahashi et al.
BIOCHEMICAL SOCIETY TRANSACTIONS (2005)
Exploiting the PI3K/AKT pathway for cancer drug discovery
BT Hennessy et al.
NATURE REVIEWS DRUG DISCOVERY (2005)
Shelterin: the protein complex that shapes and safeguards human telomeres
T de Lange
GENES & DEVELOPMENT (2005)
PI 3-kinase p110β:: a new target for antithrombotic therapy
SP Jackson et al.
NATURE MEDICINE (2005)
The plasticity of aging: Insights from long-lived mutants
C Kenyon
CELL (2005)
PI3K-Akt pathway: Its functions and alterations in human cancer
M Osaki et al.
APOPTOSIS (2004)
Targeted deletion reveals an essential function for the telomere length regulator Trf1
J Karlseder et al.
MOLECULAR AND CELLULAR BIOLOGY (2003)
TRF1 is degraded by ubiquitin-mediated proteolysis after release from telomeres
W Chang et al.
GENES & DEVELOPMENT (2003)
Identification of a proline-rich Akt substrate as a 14-3-3 binding partner
KS Kovacina et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Transformation of normal human cells in the absence of telomerase activation
YR Seger et al.
CANCER CELL (2002)
The protein kinase B/Akt signalling pathway in human malignancy
KM Nicholson et al.
CELLULAR SIGNALLING (2002)
Role for the related poly(ADP-ribose) polymerases tankyrase 1 and 2 at human telomeres
BD Cook et al.
MOLECULAR AND CELLULAR BIOLOGY (2002)
The shortest telomere, not average telomere length, is critical for cell viability and chromosome stability
MT Hemann et al.
CELL (2001)
TANK2, a new TRF1-associated poly(ADP-ribose) polymerase, causes rapid induction of cell death upon overexpression
PG Kaminker et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Restoration of telomerase activity rescues chromosomal instability and premature aging in Terc-/- mice with short telomeres
E Samper et al.
EMBO REPORTS (2001)
Telomerase-deficient mice with short telomeres are resistant to skin tumorigenesis
E González-Suárez et al.
NATURE GENETICS (2000)
分享论文
